Pierre Koch

List of Publications by Year
in descending order

46 papers	1,018 citations	471371 17 h-index	434063 31 g-index
49 all docs	49 docs citations	49 times ranked	1385 citing authors

#	Article	IF	Citations
1	Design and Synthesis of Highly Selective Brain Penetrant p38Î± Mitogen-Activated Protein Kinase Inhibitors. Journal of Medicinal Chemistry, 2022, 65, 1225-1242.	2.9	7
2	Addressing a Trapped High-Energy Water: Design and Synthesis of Highly Potent Pyrimidoindole-Based Glycogen Synthase Kinase-3Î² Inhibitors. Journal of Medicinal Chemistry, 2022, 65, 1283-1301.	2.9	9
3	Structure-Based Design of High-Affinity Fluorescent Probes for the Neuropeptide Y Y₁ Receptor. Journal of Medicinal Chemistry, 2022, 65, 4832-4853.	2.9	10
4	1-{3-[(7-Fluoro-9H-pyrimido[4,5-b]indol-4-yl)(methyl)amino]piperidin-1-yl}propan-1-one. IUCrData, 2021, 6, .	0.1	0
5	Genetic Engineering in Combination with Semiâ€Synthesis Leads to a New Route for Gramâ€Scale Production of the Immunosuppressive Natural Product Brasilicardinâ€…A. Angewandte Chemie - International Edition, 2021, 60, 13536-13541.	7.2	12
6	Genetic Engineering in Combination with Semiâ€Synthesis Leads to a New Route for Gramâ€Scale Production of the Immunosuppressive Natural Product Brasilicardinâ€…A. Angewandte Chemie, 2021, 133, 13648-13653.	1.6	0
7	Selective mono-de-O-acetylation of the per-O-acetylated brasilicardin carbohydrate side chain. Carbohydrate Research, 2021, 504, 108312.	1.1	0
8	Controlling the Covalent Reactivity of a Kinase Inhibitor with Light. Angewandte Chemie - International Edition, 2021, 60, 20178-20183.	7.2	23
9	Controlling the Covalent Reactivity of a Kinase Inhibitor with Light. Angewandte Chemie, 2021, 133, 20340-20345.	1.6	2
10	Discovery and Evaluation of Enantiopure 9H-pyrimido[4,5-b]indoles as Nanomolar GSK-3Î² Inhibitors with Improved Metabolic Stability. International Journal of Molecular Sciences, 2020, 21, 7823.	1.8	6
11	Inhibitors of c-Jun N-Terminal Kinase 3. Topics in Medicinal Chemistry, 2020, , 203-224.	0.4	2
12	(2S,3â€²S,3a'R,5â€²R,7a'R)-5â€²-[(E)-5-(Furan-3-yl)-2-methylpent-1-en-1-yl]-3-hydroxy-3â€²,4, IUCrData, 2020, 5, .	0.1	1
13	Design, Synthesis and Biological Evaluation of 7-Chloro-9H-pyrimido[4,5-b]indole-based Glycogen Synthase Kinase-3Î² Inhibitors. Molecules, 2019, 24, 2331.	1.7	11
14	Pyridinylimidazoles as GSK3Î² Inhibitors: The Impact of Tautomerism on Compound Activity via Water Networks. ACS Medicinal Chemistry Letters, 2019, 10, 1407-1414.	1.3	12
15	Pyridinylimidazoles as dual glycogen synthase kinase 3Î²/p38Î± mitogen-activated protein kinase inhibitors. European Journal of Medicinal Chemistry, 2019, 175, 309-329.	2.6	26
16	N1-{4-[2-(Methylthio)-1H-imidazol-5-yl]pyridin-2-yl}benzene-1,4-diamine. MolBank, 2019, 2019, M1048.	0.2	1
17	Das Cysteinom der Proteinkinasen als Zielstruktur in der Arzneistoffentwicklung. Angewandte Chemie, 2018, 130, 4456-4470.	1.6	9
18	The Cysteinome of Protein Kinases as a Target in Drug Development. Angewandte Chemie - International Edition, 2018, 57, 4372-4385.	7.2	173

#	Article	IF	Citations
19	InnenrÃ¼cktitelbild: Das Cysteinom der Proteinkinasen als Zielstruktur in der Arzneistoffentwicklung (Angew. Chem. 16/2018). Angewandte Chemie, 2018, 130, 4517-4517.	1.6	0
20	The Symmetric Tetravalent Sulfhydryl-Specific Linker NATBA Facilitates a Combinatorial â€œTool Kitâ€• Strategy for Phage Display-Based Selection of Functionalized Bicyclic Peptides. ACS Omega, 2018, 3, 12361-12368.	1.6	10
21	Switching Between Bicyclic and Linear Peptides â€" The Sulfhydryl-Specific Linker TPSMB Enables Reversible Cyclization of Peptides. Frontiers in Chemistry, 2018, 6, 484.	1.8	7
22	A Diverse and Versatile Regiospecific Synthesis of Tetrasubstituted Alkylsulfanylimidazoles as p38Î± Mitogen-Activated Protein Kinase Inhibitors. Molecules, 2018, 23, 221.	1.7	6
23	Structural Optimization of a Pyridinylimidazole Scaffold: Shifting the Selectivity from p38Î± Mitogen-Activated Protein Kinase to c-Jun N-Terminal Kinase 3. ACS Omega, 2018, 3, 7809-7831.	1.6	24
24	(2S,3S)-2-Azaniumyl-4-[(1S,4aS,4bS,6S,7S,8aS,10aS)-6,7-dihydroxy-2,4b,8,8,10a-pentamethyl-1,4,4a,4b,5,6,7,8,8a,9,10,10a-dodecahydr (1/1/1). IUCrData, 2018, 3, .	0.1	1
25	SK4 channels modulate Ca²⁺ signalling and cell cycle progression in murine breast cancer. Molecular Oncology, 2017, 11, 1172-1188.	2.1	43
26	Fluorescence polarization-based competition binding assay for c-Jun N-terminal kinases 1 and 2. Analytical Biochemistry, 2017, 532, 26-28.	1.1	9
27	Tri- and Tetrasubstituted Pyridinylimidazoles as Covalent Inhibitors of c-Jun N-Terminal Kinase 3. Journal of Medicinal Chemistry, 2017, 60, 594-607.	2.9	46
28	2â€Alkylsulfanylâ€4(5)â€arylâ€5(4)â€heteroarylimidazoles: An Overview on Synthetic Strategies and Biological Activity. Archiv Der Pharmazie, 2017, 350, 1700258.	2.1	9
29	From 2-Alkylsulfanylimidazoles to 2-Alkylimidazoles: An Approach towards Metabolically More Stable p38Î± MAP Kinase Inhibitors. Molecules, 2017, 22, 1729.	1.7	10
30	High-Quality Draft Genome Sequence of the Actinobacterium Nocardia terpenica IFM 0406, Producer of the Immunosuppressant Brasilicardins, Using Illumina and PacBio Technologies. Genome Announcements, 2016, 4, .	0.8	14
31	11th German Conference on Chemoinformatics (GCC 2015). Journal of Cheminformatics, 2016, 8, 18.	2.8	1
32	Fluorescence polarization-based assays for detecting compounds binding to inactive c-Jun N-terminal kinase 3 and p38Î± mitogen-activated protein kinase. Analytical Biochemistry, 2016, 503, 28-40.	1.1	22
33	1-(3â€²,6â€²-Dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9â€²-xanthen]-5-yl)-3-[4-({4-[1-(4-fluorophenyl)-1H-imidazol-5-yl]pyridin-2-yl} methanol monosolvate. IUCrData, 2016, 1, .	0.1	0
34	c-JunN-terminal kinase inhibitors: a patent review (2010 â€" 2014). Expert Opinion on Therapeutic Patents, 2015, 25, 849-872.	2.4	47
35	Tetra-Substituted Pyridinylimidazoles As Dual Inhibitors of p38Î± Mitogen-Activated Protein Kinase and c-Jun N-Terminal Kinase 3 for Potential Treatment of Neurodegenerative Diseases. Journal of Medicinal Chemistry, 2015, 58, 443-456.	2.9	43
36	Synthesis and Bioactivity of a Brasilicardin A Analogue Featuring a Simplified Core. Organic Letters, 2015, 17, 3608-3611.	2.4	17

#	Article	IF	Citations
37	An optimized and versatile synthesis to pyridinylimidazole-type p38Î± mitogen activated protein kinase inhibitors. Organic and Biomolecular Chemistry, 2015, 13, 10699-10704.	1.5	4
38	Targeting the Gatekeeper MET146 of C-Jun N-Terminal Kinase 3 Induces a Bivalent Halogen/Chalcogen Bond. Journal of the American Chemical Society, 2015, 137, 14640-14652.	6.6	73
39	Inhibitors of c-Jun N-Terminal Kinases: An Update. Journal of Medicinal Chemistry, 2015, 58, 72-95.	2.9	81
40	An Efficient Synthesis of the Protected Carbohydrate Moiety of Brasilicardin A. Organic Letters, 2011, 13, 3710-3713.	2.4	23
41	Tri- and tetrasubstituted imidazoles as p38Î± mitogen-activated protein kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 6671-6675.	1.0	36
42	Unexpected Reaction of 2-Alkylsulfanylimidazoles to Imidazol-2-ones: Pyridinylimidazol-2-ones as Novel Potent p38Î± Mitogen-Activated Protein Kinase Inhibitors. Journal of Medicinal Chemistry, 2010, 53, 4798-4802.	2.9	15
43	Pyridinylquinoxalines and Pyridinylpyridopyrazines as Lead Compounds for Novel p38Î± Mitogen-Activated Protein Kinase Inhibitors. Journal of Medicinal Chemistry, 2010, 53, 1128-1137.	2.9	28
44	Role of the Hydrogen Bonding Heteroatomâ‹¯Lys53 Interaction between the p38Î± Mitogen-Activated Protein (MAP) Kinase and Pyridinyl-Substituted 5-Membered Heterocyclic Ring Inhibitors. Journal of Medicinal Chemistry, 2009, 52, 2613-2617.	2.9	32
45	Targeting the Ribose and Phosphate Binding Site of p38 Mitogen-Activated Protein (MAP) Kinase: Synthesis and Biological Testing of 2-Alkylsulfanyl-, 4(5)-Aryl-, 5(4)-Heteroaryl-Substituted Imidazoles. Journal of Medicinal Chemistry, 2008, 51, 5630-5640.	2.9	66
46	Towards the improvement of the synthesis of novel 4(5)-aryl-5(4)-heteroaryl-2-thio-substituted imidazoles and their p38 MAP kinase inhibitory activity. Organic and Biomolecular Chemistry, 2008, 6, 437-439.	1.5	33